September 2020 in “Oxford University Press eBooks” This article discusses how understanding a genetic condition with a 5-alpha reductase mutation led to developing finasteride to treat benign prostatic hyperplasia and male pattern baldness, reporting no new research results.
April 2013 in “e-Jurnal Medika Udayana” This abstract indicates that finasteride, at a dose of 1 mg per day, is effective in treating androgenetic alopecia in men by significantly reducing DHT levels.
24 citations
,
September 2002 in “Der Urologe” A stronger dual 5α-reductase inhibitor could improve treatment for benign prostatic hyperplasia by further reducing DHT levels.
June 2001 in “International Journal of Cosmetic Surgery and Aesthetic Dermatology” This review discusses advances in 5α-reductase inhibitors for treating male androgenetic alopecia and reports no new clinical results.
65 citations
,
October 1999 in “Journal of The American Academy of Dermatology” In this study, finasteride doses as low as 0.2 mg per day significantly reduced both scalp skin and serum DHT levels in men with androgenetic alopecia.
3 citations
,
June 1996 in “PubMed” This review discusses the effects and potential benefits of finasteride in treating hirsutism and androgenetic alopecia but reports no new clinical results.
59 citations
,
September 1994 in “The Journal of Clinical Endocrinology and Metabolism” This study found that 4 weeks of finasteride treatment significantly decreased DHT levels in bald scalp to levels similar to hair-containing scalp in men with male pattern baldness.
30 citations
,
August 1992 in “The Journal of Clinical Endocrinology and Metabolism” This study found that lowering serum DHT levels with 5 mg finasteride daily did not significantly alter serum gonadotropin levels in healthy young men after 28 days.
211 citations
,
November 1990 in “The Journal of Steroid Biochemistry and Molecular Biology” Finasteride effectively treats BPH, but needs more trials to understand potential.
